| WINT Stock | | | USD 0.50 0.01 1.96% |
President
Dr. Steven G. Simonson, M.D., is Senior Vice President and Chief Development Officer of Discovery Laboratories, Inc., since October 2014. He served as Vice President, Clinical Development, since joining the Company in May of 2014. Dr. Simonson brings over 25 years of medical practice and pharmaceutical industry clinical trial experience with a significant background in pulmonary critical care and developing respiratory drugs to the Company, including preclinical, first time into man and phases 14, and IND, NDA and sNDA experience. Dr. Simonson spent 15 years at AstraZeneca Pharmaceuticals. He was involved in or led several successful IND and NDA filings including the Pulmicort Turbuhaler M3 NDA, which was approved for treatment of asthma. He spent the next two years as Vice President of Clinical Development at Agennix, Inc., a biopharmaceutical company primarily focused in oncology and sepsis, leading programs including studies of talactoferrin in necrotizing enterocolitis, the second most common cause of morbidity in premature neonates. Most recently, Dr. Simonson was an Executive Director in the Molecule Development Group at Covance. Dr. Simonson completed training in internal medicine followed by a fellowship in pulmonary and critical care medicine at Duke University Medical Center. He then held several faculty appointments at Duke in the departments of Anesthesiology and Medicine, including the divisions of Pulmonary and Critical Care Medicine. He is a Fellow of the American College of Chest Physicians, and author or coauthor of multiple peer reviewed publications, abstracts, posters and chapters since 2014.
| Age | 65 |
| Tenure | 10 years |
| Address | 2600 Kelly Road, Warrington, PA, United States, 18976-3622 |
| Phone | 215 488 9300 |
| Web | https://windtreetx.com |
Simonson received his medical degree from the Medical College of Wisconsin, and his Masters of Health Sciences degree in Biometry from the Duke University School of Medicine.
Windtree Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.508) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -2.98 in 2024.
Return On Capital Employed is likely to drop to -0.65 in 2024.
Liabilities And Stockholders Equity is likely to gain to about 42.3
M in 2024, whereas
Total Current Liabilities is likely to drop slightly above 3.8
M in 2024.
Windtree Therapeutics currently holds 16.83
M in liabilities with Debt to Equity
(D/E) ratio of 0.95, which is about average as compared to similar companies. Windtree Therapeutics has a current ratio of 2.42, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Windtree Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. Windtree Therapeutics (WINT) is traded on NASDAQ Exchange in USA. It is located in 2600 Kelly Road, Warrington, PA, United States, 18976-3622 and employs 12 people. Windtree Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Windtree Therapeutics Leadership Team
Elected by the shareholders, the Windtree Therapeutics' board of directors comprises two types of representatives: Windtree Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Windtree. The board's role is to monitor Windtree Therapeutics' management team and ensure that shareholders' interests are well served. Windtree Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Windtree Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Cox, Vice Operations | |
| Eric MBA, Senior COO | |
| Jamie McAndrew, Controller, VP | |
| John Tattory, CFO, Senior Vice President | |
| Pratap Paruchuru, Executive Development | |
| Craig Fraser, President CEO, Director | |
| Steven Simonson, Senior Vice President and Chief Development Officer | |
| Ronald Dundore, Ex Quality | |
| MHS MD, Senior Officer | |
| Tracy Rarick, Head Management | |
| Diane Esq, Sr Counsel | |
| John CPA, CFO, VP | |
Windtree Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Windtree Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to
measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.